Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
30 Results for "
zonal heterogeneity
" in MedChemExpress (MCE) Product Catalog:
Products (30)
30 Results for "zonal heterogeneity" in MCE Product Catalog:
Cat. No.: HY-D3368
Target:
Research Areas:
DMA-SiRd is a fluorescent probe that can be used for crosstalk-free dual-channel imaging of lipid droplets and mitochondria, mapping of lipid microenvironment heterogeneity, and imaging of lipid droplet-mitochondria interactions. DMA-SiRd has two imaging channels: Ex/Em = 633/650-750 nm and Ex/Em = 546/570-620 nm, with two-photon excitation wavelengths of 1040 nm and 1200 nm for brain imaging. DMA-SiRd can be applied to the research of atherosclerosis .
Cat. No.: HY-K6143
MCE Mouse Fetal Brain Organoid (Expansion) Kit contains Mouse Fetal Brain Organoid Expansion Basal Medium and Mouse Fetal Brain Organoid Expansion Culture Supplement . This kit enables the efficient in vitro generation of mouse fetal brain organoids (mFBs). Within this culture system, mouse fetal brain tissue can spontaneously form organoid structures that faithfully recapitulate key features of in vivo cellular heterogeneity and complex tissue organization.
Cat. No.: HY-16738AR
CAS No.: 1448754-43-5
Synonyms: GS 6615 hydrochloride (Standard)
Research Areas:
Eleclazine (hydrochloride) (Standard) is the analytical standard of Eleclazine (hydrochloride). This product is intended for research and analytical applications. Eleclazine (GS 6615) hydrochloride is a selective cardiac late sodium current inhibitor and a weak inhibitor of potassium current with IC50 value of <1 μM and approximately 14.2 μM, respectively. Eleclazine hydrochloride shows concurrent protection against autonomically induced atrial premature beats, repolarization alternans and heterogeneity, and atrial fibrillation in porcine model. Eleclazine hydrochloride can be used to research cardiac arrhythmias .
Cat. No.: HY-186083
CAS No.: 36167-80-3
Target:
Research Areas:
Propylbenzilylcholine mustard (PrBCM) is an irreversible, covalently binding selective antagonist targeting rat cardiac muscarinic receptors, with a preference for muscarinic receptor subtypes that show low affinity for agonists. Propylbenzilylcholine mustard inactivates such receptors in a dose- and time-dependent manner in vitro, and its receptor selectivity remains stable across different ionic strengths and in GTP-containing buffer systems. Propylbenzilylcholine mustard can be applied to basic pharmacological studies on the structure and function of muscarinic receptors, especially focusing on the heterogeneity of cardiac muscarinic receptors and related cardiovascular pharmacological research .
Cat. No.: HY-175076
Target:
Research Areas:
Globotriaosylceramide (non-hydroxy) (porcine RBC) is a glycosphingolipid found in the cell membranes of mammals. Globotriaosylceramide (non-hydroxy) (porcine RBC) is the core pathogenic molecule of Fabry disease, and its level can be downregulated by supplementing α-galactosidase A. Globotriaosylceramide (non-hydroxy) (porcine RBC) amplifies B-cell receptor signals by regulating the localization of co-receptor CD19, and can be used as a vaccine adjuvant, capable of guiding the generation of broad-spectrum and cross-protective antibody responses. Globotriaosylceramide (non-hydroxy) (porcine RBC) promotes wound healing and reduces scar formation by regulating fibroblast heterogeneity .
Cat. No.: HY-180306
CAS No.: 84693-92-5
Research Areas:
Fluoroestradiol is an Estrogen receptor PET imaging tracer precursor. Fluoroestradiol, when radiolabeled with 18F, can be used as an Estrogen receptor PET imaging tracer. 18F-Fluoroestradiol exhibits the highest uptake selectivity and target-to-background ratio among
several 18F-labeled estrogens. 18F-Fluoroestradiol has demonstrated Estrogen receptor expression in normal brain tissues and in meningiomas. 18F-Fluoroestradiol can quantify regional Estrogen receptor expression in breast cancer. 18F-Fluoroestradiol has potential applications in assessing and monitoring heterogeneity in ovarian cancer .
several 18F-labeled estrogens. 18F-Fluoroestradiol has demonstrated Estrogen receptor expression in normal brain tissues and in meningiomas. 18F-Fluoroestradiol can quantify regional Estrogen receptor expression in breast cancer. 18F-Fluoroestradiol has potential applications in assessing and monitoring heterogeneity in ovarian cancer .
Cat. No.: HY-D3112
Target:
Research Areas:
P2-Aggregate is a polarity-sensitive fluorescent probe for protein aggregation, which is based on the Nile Red scaffold and modified with a morpholine ring to enhance water solubility. P2-Aggregate improves anti-precipitation ability in aqueous phase via morpholine ring modification, and enables site-specific labeling of target proteins by combining with HaloTag technology. Utilizing the property that its emission wavelength blue-shifts with decreasing local polarity (excited at 543 nm), P2-Aggregate quantitatively detects changes in local polarity during protein aggregation and polarity heterogeneity inside aggregates in living cells. P2-Aggregate can be used in the research of diseases associated with the aggregation of Htt-110Q and SOD1 proteins, such as Huntington's disease and amyotrophic lateral sclerosis .
Cat. No.: HY-D3391
Cat. No.: HY-D3072
Research Areas:
P6-Aggrate is a fluorescent probe for aggregated proteome detection. P6-Aggrate specifically recognizes amorphous aggregated proteomes through non-covalent reversible binding, and its fluorescence enhances after heat-induced protein aggregation. P6-Aggrate reflects the polarity and compactness heterogeneity within aggregated proteomes via emission wavelength shift: short-wavelength emission (blue shift) corresponds to large aggregates with high compactness, while long-wavelength emission (red shift) corresponds to small spots with low compactness (Ex/Em = 488/520-580 nm). P6-Aggrate enables reversible monitoring of the dynamic processes of formation and clearance of stress-induced proteome aggregation such as that induced by MG132 (HY-13259) in living cells. P6-Aggrate can be used in studies related to protein homeostasis imbalance, neurodegenerative diseases and protein aggregation .
Cat. No.: HY-L169
706 compounds
Resistance refers to the decrease in the effectiveness of drugs in treating diseases or symptoms. Due to the increasing global antibiotic resistance, it may threaten our ability to treat common infectious diseases. Drug resistance is also the main cause of chemotherapy failure in malignant tumors. In approximately 50% of cases, drug resistance exists even before chemotherapy begins. There are many mechanisms of anticancer drug resistance, including increased protein expression that leads to drug removal, mutations in drug binding sites, recovery of tumor protein production, and pre-existing genetic heterogeneity in tumor cell populations. In addition, the issue of drug resistance seems to have affected the development of new anticancer drugs. Drug resistance may be caused by various conditions, such as mutations, epigenetic modifications, and upregulation of drug efflux protein expression. Overcoming multidrug resistance in cancer treatment is becoming increasingly important.
MCE designs a unique collection of 706 anti-drug-resistant compounds. It is a good tool to be used for research on cancer and other diseases.
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
